WallStreetZenWallStreetZen

NASDAQ: FATE
Fate Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for FATE

Based on 4 analysts offering 12 month price targets for Fate Therapeutics Inc

Min Forecast
$3.50+50.21%
Avg Forecast
$6.38+173.61%
Max Forecast
$8.00+243.35%

Should I buy or sell FATE stock?

Based on 4 analysts offering ratings for Fate Therapeutics Inc.

Buy
Strong Buy
1 analysts 25%
Buy
2 analysts 50%
Hold
1 analysts 25%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although FATE's forecast from analysts indicates a "Buy", our proven Zen Rating quant model rates FATE as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +5.11% per year. Learn More

Be the first to know when Wall Street analysts revise their FATE stock forecasts and price targets.

FATE stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-08-14
lockedlocked$00.00+00.00%2026-08-14
lockedlocked$00.00+00.00%2026-08-14
lockedlocked$00.00+00.00%2026-06-08

1 of 1

Forecast return on equity

Is FATE forecast to generate an efficient return?

Company
-78.26%
Industry
15.36%
Market
166.96%
FATE's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is FATE forecast to generate an efficient return on assets?

Company
-46.17%
Industry
23.16%
FATE is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

FATE earnings per share forecast

What is FATE's earnings per share in the next 3 years based on estimates from 14 analysts?

Avg 1 year Forecast
-$1.10
Avg 2 year Forecast
-$1.05
Avg 3 year Forecast
-$1.10

FATE revenue forecast

What is FATE's revenue in the next 3 years based on estimates from 14 analysts?

Avg 1 year Forecast
$5.4M-17.15%
Avg 2 year Forecast
$5.3M-17.67%
Avg 3 year Forecast
$4.4M-32.55%
FATE's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

FATE revenue growth forecast

How is FATE forecast to perform vs Biotechnology companies and vs the US market?

Company
-10.79%
Industry
32.4%
Market
13.27%
FATE's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
FATE's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

FATE vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
FATE$2.33$6.38+173.61%Buy
ELDN$3.45$12.00+247.83%Strong Buy
CAMP$4.48$9.30+107.59%Strong Buy
TTRX$9.46$8.00-15.43%Strong Buy
SRZN$23.99$42.00+75.07%Strong Buy
View Top Biotech Stocks

Fate Therapeutics Stock Forecast FAQ

Is Fate Therapeutics Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 4 Wall Street analysts covering (NASDAQ: FATE) stock is to Buy FATE stock.

Out of 4 analysts, 1 (25%) are recommending FATE as a Strong Buy, 2 (50%) are recommending FATE as a Buy, 1 (25%) are recommending FATE as a Hold, 0 (0%) are recommending FATE as a Sell, and 0 (0%) are recommending FATE as a Strong Sell.

If you're new to stock investing, here's how to buy Fate Therapeutics stock.

What is FATE's earnings growth forecast for 2026-2028?

(NASDAQ: FATE) Fate Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 10.47%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 30.28%.

Fate Therapeutics's earnings in 2026 is -$125,996,000.On average, 14 Wall Street analysts forecast FATE's earnings for 2026 to be -$132,257,883, with the lowest FATE earnings forecast at -$142,083,166, and the highest FATE earnings forecast at -$118,262,847. On average, 13 Wall Street analysts forecast FATE's earnings for 2027 to be -$125,991,270, with the lowest FATE earnings forecast at -$160,871,022, and the highest FATE earnings forecast at -$95,616,770.

In 2028, FATE is forecast to generate -$131,622,835 in earnings, with the lowest earnings forecast at -$192,575,530 and the highest earnings forecast at -$75,486,924.

What is FATE's revenue growth forecast for 2026-2028?

(NASDAQ: FATE) Fate Therapeutics's forecast annual revenue growth rate of -10.79% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.4%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.27%.

Fate Therapeutics's revenue in 2026 is $6,491,000.On average, 14 Wall Street analysts forecast FATE's revenue for 2026 to be $644,394,724, with the lowest FATE revenue forecast at $0, and the highest FATE revenue forecast at $2,050,608,277. On average, 13 Wall Street analysts forecast FATE's revenue for 2027 to be $640,320,827, with the lowest FATE revenue forecast at $0, and the highest FATE revenue forecast at $2,516,230,794.

In 2028, FATE is forecast to generate $524,574,210 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $1,698,455,786.

What is FATE's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: FATE) forecast ROA is -46.17%, which is lower than the forecast US Biotechnology industry average of 23.16%.

What is FATE's Price Target?

According to 4 Wall Street analysts that have issued a 1 year FATE price target, the average FATE price target is $6.38, with the highest FATE stock price forecast at $8.00 and the lowest FATE stock price forecast at $3.50.

On average, Wall Street analysts predict that Fate Therapeutics's share price could reach $6.38 by Aug 14, 2027. The average Fate Therapeutics stock price prediction forecasts a potential upside of 173.61% from the current FATE share price of $2.33.

What is FATE's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: FATE) Fate Therapeutics's current Earnings Per Share (EPS) is -$1.05. On average, analysts forecast that FATE's EPS will be -$1.10 for 2026, with the lowest EPS forecast at -$1.19, and the highest EPS forecast at -$0.99. On average, analysts forecast that FATE's EPS will be -$1.05 for 2027, with the lowest EPS forecast at -$1.34, and the highest EPS forecast at -$0.80. In 2028, FATE's EPS is forecast to hit -$1.10 (min: -$1.61, max: -$0.63).

What is FATE's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: FATE) forecast ROE is -78.26%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.